investorscraft@gmail.com

Intrinsic value of Quest Diagnostics Incorporated (DGX)

Previous Close$152.61
Intrinsic Value
Upside potential
Previous Close
$152.61

VALUATION INPUT DATA (original, your and others' valuations)

ParameterOrig.Your
Date of valuation (DoV)  
Intrinsic value (IV) at DoV, $/sh  
IV at current val. algorithm, $/sh107.36 

The original valuation is based on fiscal year data as of 2021-12-31 and quarterly data as of 2022-09-30.

Registered users can save their valuation input data

  1. Annual
  2. Quarterly YoY
  3. Quarterly QoQ

Annual revenue growth rates, % (past and forecasted)

NOTE: The bar chart shows historic and forecasted yearly revenue growth rates. Its purpose is to help you in determining what initial revenue rate you want to base your stock valuation on. Please make sure that you are confident in the value you select - for most stocks it is by far the most important parameter in valuation.

Company description

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2021(a)2022202320242025202620272028202920302031203220332034203520362037203820392040204120422043204420452046

INCOME STATEMENT

Revenue growth rate, %14.3NaN
Revenue, $10788NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $m8407NaN
Operating income, $m2381NaN
EBITDA, $m2789NaN
Interest expense (income), $mNaN
Earnings before tax, $m2585NaN
Tax expense, $m597NaN
Net income, $m1988NaN

BALANCE SHEET

Cash and short-term investments, $m872NaN
Total assets, $m13611NaN
Adjusted assets (=assets-cash), $m12739NaN
Average production assets, $m10419NaN
Working capital, $m988NaN
Total debt, $m4773NaN
Total liabilities, $m7167NaN
Total equity, $m6444NaN
Debt-to-equity ratio0.741NaN
Adjusted equity ratio0.459NaN

CASH FLOW

Net income, $m1988NaN
Depreciation, amort., depletion, $m408NaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $m2233NaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $m-403NaN
Free cash flow, $m2636NaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $m988
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount